Connect with us


Weekly Covid-19 Update – June 4, 2021: Delaware Cases Continue Downward Trend



DOVER (June 4, 2021) – The Delaware Division of Public Health (DPH) will provide an update on the latest statistics on Coronavirus Disease 2019 (COVID-19) in Delaware on Thursday, June 3, 2021 at 6:00 p.m.

As of March 11, 2020, a total of 109,005 positive COVID-19 cases have been reported to the DPH among residents of Delaware. The seven-day average of new positive cases decreased to 48.4 on Thursday, June 3.

On Tuesday June 1, the seven-day average for the percentage of total positive tests was 2.0%, down from 2.7% on Tuesday May 25. There is a two day delay in the presentation of percent data of tests that are positive to account for the time lag between the test date and the date DPH receives the test result.

Additionally, 51 people are currently being hospitalized in Delaware due to COVID-19, 11 fewer than at this point last week. Five of the hospitalized people are seriously ill, four less than last week.

A total of 1,674 Delaware residents have died as a result of COVID-19. The state has reported 14 additional deaths since last week’s update. The total number of people who have died from COVID-19 ranges from younger than 5 to 104 years. Of the deceased, 838 were female and 836 were male. A total of 832 people were from New Castle County, 345 from Kent County and 497 from Sussex County.

DE wins! To update

DPH director Dr. Karyl Rattay contacted the first DE Wins! Raffle prize drawing on Thursday. Prizes were US $ 5,000 plus two annual passes to a Delaware State Park and a Luxury Suite Package to the Wilmington Blue Rocks. DPH is waiting for the winners to return the approval documents before the names with DE Wins! can share. DE wins! The organizers will provide the names of those who have given permission to the state, insofar as they are able to do so. Friday’s raffle prize drawing includes $ 5,000 and Firefly tickets. To find a suitable vaccination location in Delaware and qualify for the next DE Wins! Drawing, go to:

Update on COVID-19 variant cases in Delaware:

To date, the Department of Public Health has identified the following COVID-19 variants in Delaware through routine monitoring of test samples. These variants are based on the Center for Disease Control and Prevention (CDC) list of Concerning and Interesting Variants.

Worrying variants

Variants of Interest



Number of cases



Number of cases


United Kingdom



New York, USA



South Africa



New York, USA



California, USA



New York, USA



California, USA








In total, the cases include 990 adults between the ages of 18 and 98 and 223 people under the age of 18. A total of 920 people were from New Castle County, 168 from Kent County and 125 from Sussex County.

The Delaware Public Health Laboratory has sequenced 2,915 samples for COVID-19 variant strains to date, including 182 in the last week.

Virus mutations are common. Public health approaches and treatments do not currently differ, but as these variants can be more contagious, it is even more important that those who are not fully vaccinated remain vigilant and continue to take the necessary steps to keep the virus from spreading to avoid – wear a mask, wash hands, avoid accumulation.

Science is clear that the vaccines are extremely safe and effective – and Delawareers who are fully vaccinated have significant protection from COVID-19 infections and serious illnesses. We would encourage all Delawareeans to get vaccinated – []

Further information on the classification of CDC variants can be found at

COVID-19 vaccinations:

As of June 4 at 00:01 a.m., a total of 927,661 administered doses of the COVID-19 vaccine had been reported to the government vaccination information system DelVAX. A total of 827,280 cans were shipped to the state and 364,575 cans were dispensed under the state provider programs.

For the latest Delaware COVID-19 vaccination statistics, visit the Vaccine Tracker dashboard at For the latest information on the COVID-19 vaccine and the introduction of vaccinations in Delaware, visit

Breakthrough cases:

Vaccination significantly reduces the likelihood of contracting or getting seriously ill with COVID-19. To date, 392,753 Delaware residents have been fully vaccinated. Of those, there have been 344 breakthrough cases of COVID-19, less than a tenth of a percent. A breakthrough case is defined as testing positive for COVID-19 after a person has been fully vaccinated for two weeks or more – although that doesn’t mean the infection actually appeared after vaccination. Fifteen of the breakthrough cases reported involved hospital stays and four resulted in death. Breakthrough cases are extremely rare and science is clear that the best way to prevent serious illness from COVID-19 is to get vaccinated.

Care statistics:

On June 6th, 6:00 p.m., there were a total of 2,739 positive cases of COVID-19 with long-term care residents, and 757 residents of long-term care facilities in Delaware have died from complications related to COVID-19.

Stay home if you have any of the following symptoms: fever, cough, shortness of breath, sore throat, muscle pain, tiredness, chills, chills, loss of smell or taste, nausea or vomiting, diarrhea or headache, or stuffy or runny nose with no known cause like allergies. Other symptoms, such as abdominal pain or loss of appetite, have been identified as potential symptoms related to COVID-19 and may lead to further screening, action, or examinations by a family doctor. If you are sick and need essential supplies, ask someone to go to the grocery store or pharmacy to get what you need.

DPH reminds Delawareans that if you believe you have been exposed to someone with COVID-19 or have symptoms of illness, you should distance yourself from others, especially vulnerable populations. Older adults and people of all ages with serious underlying medical conditions – including severe heart disease, chronic lung conditions including moderate to severe asthma, severe obesity, and people with immunodeficiency, including those who have been treated for cancer – may be at greater risk of developing serious illness due to COVID-19.

Information on testing events, including community test sites, permanent fixed test sites, and stand-alone sites operated by the healthcare systems and hospitals, is listed in the test section of the Delaware coronavirus website at

Delawareans 18+ are encouraged to download COVID Alert DE, Delaware’s free exposure notification app, to help keep your neighbors safe while maintaining your privacy. Download it from the App Store or Google Play.

People with general questions about COVID-19 should call Delaware 2-1-1, deaf or hard of hearing people can send their zip code to 898-211 or email Opening times are:

Monday – Friday: 8:00 a.m. to 9:00 p.m.

Saturday: 9:00 a.m. to 5:00 p.m.

Medically-related questions about tests, symptoms, and health-related guidelines can be emailed to

Individuals who have complaints about individuals violating restrictions on public gatherings should contact their state or local law enforcement agency. Concerns that a company may violate operating restrictions should be directed to: Questions related to business reopening or operations when businesses reopen should be directed to Questions about unemployment claims should be emailed to:

As a reminder, DPH recently announced that it has created a way for the public to file complaints if they believe a COVID-19 vaccination provider is violating vaccination regulations. These complaints can be directed to

DPH will continue to update the public as more information becomes available. For the latest information on Delaware’s answer, see

image_printTo press


Kremlin blames ‘nihilism’ as Moscow sees record COVID-19 infections



A specialist wearing personal protective equipment (PPE) sprays disinfectant while disinfecting Rizhsky train station, one of the measures taken to contain the spread of coronavirus disease (COVID-19), in Moscow, Russia, June 17, 2021. Moscow Department for Russian Emergencies Ministry / Handout via REUTERS

MOSCOW, June 18 (Reuters) – The Kremlin on Friday blamed a surge in COVID-19 cases on reluctance to get vaccinated for “nihilism” after fears raised a record of 9,000 new infections in the capital third wave had stoked.

Russia, the largest country in the world, reported 17,262 new coronavirus infections nationwide.

Moscow Mayor Sergei Sobyanin extended the restrictions he had previously imposed, including a ban on public events with more than 1,000 people, the closure of cafes and restaurants at 11 p.m. and the closure of fan zones set up for the European Football Championship. Continue reading

Sobyanin said earlier this week that Moscow, home to 13 million people, was facing a new, more aggressive and contagious variant of the coronavirus and that the situation in the city was rapidly deteriorating.

It was not clear if he was referring to the Delta variant, which was first identified in India and which led to a resurgence of cases in the UK.

Kremlin spokesman Dmitry Peskov said President Vladimir Putin is closely monitoring the situation.

When asked to explain the increase in cases, Peskov blamed the virus’ “cunning nature”, an indication of its mutations, and “total nihilism and low vaccination rate”. Continue reading

At a briefing, he rejected the idea, postulated by some critics, that Russians were reluctant to vaccinate because they mistrusted the authorities.

As of June 2, the latest available census, only 18 million Russians had received at least one dose of vaccine: that is far less than most western countries for one eighth of the population.

The Moscow authorities this week ordered all workers with public functions to be vaccinated. Continue reading

Sobyanin said Friday he expected the city government to begin vaccinating migrant workers with Sputnik Light – a single dose of the Sputnik-V vaccine – early next month.

But he also said it was “vital” to give more booster doses – a third dose, in effect. He said he had just received a booster himself after being fully vaccinated twice a year ago.

He said the third dose offered was a repeat of the first dose of the double Sputnik-V vaccine.

Several Russian officials and members of the business elite, as well as some members of the public, have already secured third and fourth doses of Sputnik V, Reuters reported in April. Continue reading

How long a vaccine will protect against COVID-19 will be crucial as countries assess when or if re-vaccination is needed, and Russia’s results are closely monitored elsewhere.

Reporting by Gleb Stolyarov; Letter from Olzhas Auyezov; Editing by Maria Kisselyova

Our Standards: The Thomson Reuters Trust Principles.

Continue Reading


Global COVID-19 death toll exceeds 4 million



June 18 (Reuters) – Coronavirus-related deaths worldwide passed a dismal 4 million milestone on Thursday, as many countries struggle to get enough vaccines to keep their populations safe, according to a Reuters tally.

While the number of new cases and deaths has declined in countries like the United States and the United Kingdom, several countries are experiencing vaccine shortages as the Delta variant becomes the dominant strain worldwide.

According to a Reuters analysis, it took over a year for the COVID-19 death toll to hit 2 million, while the next 2 million were recorded in just 166 days.

The five largest countries by total deaths – the United States, Brazil, India, Russia, and Mexico – account for about 50% of all deaths worldwide, while Peru, Hungary, Bosnia, the Czech Republic, and Gibraltar have the highest death rates when populations adjust is. (Chart on worldwide cases and deaths)

Countries in Latin America are facing the worst outbreak since March, with 43 out of 100 infections reported in the region worldwide, according to a Reuters analysis. The nine countries that reported the most deaths per capita in the past week were all in Latin America.

Hospitals in Bolivia, Chile and Uruguay mostly see COVID-19 patients between the ages of 25 and 40 as the trend towards younger patients continues. In Sao Paulo, Brazil, 80% of intensive care unit (ICU) inmates are COVID-19 patients.

Rising deaths are straining the operating capacity of crematoriums in developing countries, and gravediggers in several countries have been forced to add a number of new graves to cemeteries.

India and Brazil are the countries with the highest number of reported deaths on a seven-day average each day and are still facing cremation issues and shortage of burial sites. According to a Reuters analysis, India is responsible for every third death reported worldwide on a daily basis.

Many health experts believe the official death toll is underestimated worldwide, with the World Health Organization (WHO) estimating the death toll as much higher last month.

Last week, the Indian state of Bihar significantly increased its COVID-19 death toll after discovering thousands of unreported cases, adding weight to concerns that India’s total death toll is well above the official figure.

As poorer countries struggle to vaccinate their populations due to vaccine shortages, wealthier countries have been urged to donate more to help contain the pandemic.

“The main problem in America is access to vaccines, not vaccine acceptance,” said Carissa Etienne, director of the Pan American Health Organization, on Wednesday, urging donor countries to send vaccinations as soon as possible.

The Group of Seven (G7) rich nations had pledged to provide 1 billion COVID-19 vaccinations to help poorer countries vaccinate their populations.

(Corrects the day of the week in the first paragraph)

Reporting by Roshan Abraham and Ahmed Farhatha in Bengaluru; Additional coverage from Lasya Priya M; Edited by Lisa Shumaker and Karishma Singh

Our Standards: The Thomson Reuters Trust Principles.

Continue Reading


CureVac Shares Plunge Premarket on Disappointing Covid-19 Vaccine Trial



Shares in Germany’s CureVac CVAC -3.47%

NV fell nearly in half in pre-trading hours, suggesting significant losses for investors as the market reopened after the drug company reported disappointing results from a study on its experimental Covid-19 vaccine.

Nasdaq-listed CureVac said late Wednesday that its vaccine was 47% effective against the disease in an interim analysis of a large clinical trial, a disappointing result that will likely cloud the vaccine’s prospects for wider use.

For the main listing in the US, shares fell 45% in over-the-counter trading. The shares of the Frankfurt-listed company traded 43% lower on Thursday.

The setback could hamper vaccination campaigns in Europe because the German company has a contract with the European Commission to supply up to 405 million doses, one of the bloc’s largest deals with a single company. CureVac has partnered with major pharmaceutical company GlaxoSmithKline GSK 0.22%

SPS and Novartis AG

NVS -0.13%

to help make cans.

CureVac was once considered one of the most hopeful candidates for developing a successful Covid-19 vaccine. It received support from the German government, which had a 17% stake in the company, and the company was listed in the US last August. The company had a market valuation of $ 18.29 billion at the close of trading on Wednesday.

The share price had already declined in the past few days due to growing doubts about the study and the company’s ability to get its vaccine approved in Europe in the second quarter as planned.

A government spokesman declined to comment on the interim analysis, but said it would not affect the German vaccination schedule. On its website, the German Ministry of Health no longer includes CureVac in its vaccine delivery forecasts for the remainder of 2021.

CureVac’s vaccine uses a gene-based technology, messenger RNA, similar to that used by Moderna Inc.

and Pfizer Inc.,

with his partner BioNTech SE,

Manufacture Covid-19 vaccines.

In comparison, these vaccines were at least 94% effective in large clinical trials last year before new virus variants spread significantly. The Moderna and Pfizer shots have formed the backbone of mass vaccination campaigns in the US and other countries.

CureVac’s vaccine is slightly different from the Pfizer and Moderna shots, with a formulation that allows for storage at higher temperatures than the other shots.


Receive a coronavirus briefing six days a week and a weekly health newsletter as soon as the crisis has subsided: Register here.

CureVac, together with its partner Bayer AG, carried out a combined clinical phase 2/3 study with its vaccine from December, in which around 40,000 people in 10 countries in Latin America and Europe took part.

The study volunteers received two doses of either the CureVac vaccine or a placebo, and the researchers tracked how many in each group got Covid-19.

The proliferation of new coronavirus variants may have played a role in the disappointing effectiveness, CureVac said.

Approximately 57% of Covid-19 cases for which virus sequence data was available were caused by variants of concern – those that are more easily transmitted or can cause more serious illness – and most of the remaining cases were caused by other, less characterized variants, announced the company.

“Although we had hoped for a stronger interim result, we are aware that demonstrating high efficacy in this unprecedented variety of variants is a challenge,” said Dr. Franz-Werner Haas, CEO of CureVac.

The company said the effectiveness of the vaccine in the study varied based on age, with results suggesting effectiveness in younger people but not conclusive effectiveness in those over 60 years of age.

CureVac’s early work on a Covid-19 vaccine last year first caught the attention of then-President Donald Trump. In March 2020, the German government accused the US of tricking CureVac into moving to the US to work on a vaccine.

The company continued to develop the shot after its founder, who returned as CEO, suffered a debilitating stroke and took medical break.

Write to Peter Loftus at

Copyright © 2020 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading